---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024480"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:31:43.630391+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma reports Q3 2022 cash $79.6M; Phase 3 sarcoidosis study initiated

## Summary
- Ended Q3 2022 with $79.6M in cash, restricted cash, cash equivalents and investments.
- First patient dosed in EFZO-FIT Phase 3 study of efzofitimod for pulmonary sarcoidosis; targets 264 subjects.
- Will not initiate Phase 1 for ATYR2810 this year; pursuing external non-dilutive funding.
- FDA granted Fast Track designation for efzofitimod in systemic sclerosis-associated ILD.
- Q3 R&D expenses $9.9M, G&A $3.6M; 29.0M shares outstanding.

## SEC filing metadata
- accession: 0000950170-22-024480
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/0000950170-22-024480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/life-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024480
- JSON: https://secwatch.observer/filing/0000950170-22-024480.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024480.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/0000950170-22-024480-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.